8 completed, 3 active not recruiting, 1 terminated. 6 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 2 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Epothilones: new trials by email Literature Review of Epothilones trials Research Report on Epothilones
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy Taxane, Vinorelbine, Ixabepilone - Breast Cancer, Breast Neoplasms | Terminated | University of Wisconsin, Madison | 5 | 2018-01-29 | 2024-06-25 | |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Ixabepilone, Pharmacological Study, Temsirolimus - Adult Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 22 | 2011-06-27 | 2026-11-12 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Ixabepilone, Laboratory Biomarker Analysis - Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2010-09-07 | 2019-08-08 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Bevacizumab, Carboplatin, Ixabepilone - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 349 | 2009-09-14 | 2026-11-13 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Best Practice, Ixabepilone - Bilateral Breast Carcinoma, HER2/Neu Negative | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 116 | 2009-03-30 | 2026-11-10 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 3 | Completed | National Cancer Institute (NCI) | 799 | 2008-10-13 | 2026-06-23 |
| A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer ixabepilone, docetaxel, trastuzumab - Metastatic Breast Cancer | Phase 2 | Completed | R-Pharm | 50 | 2008-02-01 | 2016-03-10 |
| Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer Ixabepilone, Paclitaxel, Cyclophosphamide - Breast Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 384 | 2007-10-01 | 2016-02-24 |
| Phase I Combination w/ Epirubicin Ixabepilone, Epirubicin - Metastatic Breast Cancer | Phase 1 | Completed | R-Pharm | 42 | 2006-08-01 | 2016-03-10 |
| Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Cancer, Breast Cancer | Phase 3 | Completed | R-Pharm | 1221 | 2003-11-01 | 2020-11-02 |
| Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | R-Pharm | 752 | 2003-09-01 | 2020-11-02 |
| A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy Epothilone - Carcinoma, Non-small-cell Lung | Phase 2 | Completed | R-Pharm | 2001-02-01 | 2016-02-10 |
Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1) · Neoplasms (1)
R-Pharm (5) · National Cancer Institute (NCI) (4) · Bristol-Myers Squibb (1) · M.D. Anderson Cancer Center (1) · University of Wisconsin, Madison (1)
United States (10) · France (5) · Italy (5) · Spain (4) · Argentina (3) · Germany (3) · Greece (3) · South Korea (3) · Taiwan (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2)
Carol Aghajanian (1) · Carolyn McCourt (1) · Funda Meric-Bernstam (1) · Hope S Rugo (1) · Keith C Bible (1) · Mark Burkard, MD, PhD (1)
PMID 21128114, PMID 21937232, PMID 24472478, PMID 17968020, PMID 25913905, PMID 26056183, PMID 27312051, PMID 28620884, PMID 29522361, PMID 33541735, PMID 34616010, PMID 35658479, PMID 37883329, PMID 39169033
U10CA027469 (2), U10CA180868 (2), P30CA014520 (1), P30CA015083 (1), R01CA234904 (1), U01CA069912 (1), U10CA031946 (1), U10CA180821 (1), UM1CA186686 (1)